1. Bioequivalence of Chiral Drugs
2. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. London: EMEA; 2001.
3. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of chiral active substances. London: EMEA; 1993.
4. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and research (CDER). Guidance for industry on bioavailability and bioequivalence studies for orally administered drug products—general considerations. Rockville, MD: FDA; 2003.
5. Pharmacological differences between R(−)-and S(+)-ibuprofen